Growth hormone treatment in short children.
A study of 31 children with short stature was initiated in 1982. They received subcutaneous injections of pituitary hGH, 0.1 IU/kg/day; no adverse effects were seen and none of the patients acquired antibodies. Only the results of the first year are presented, as final height has not yet been attained. A high growth response was seen in 29 of the 31 children; they experienced an initial rise of IGF-1, IGF-2, alkaline phosphatase and procollagen III. The best response was obtained in the child with the lowest levels of endogenous pulsatile hGH secretion.
Albertsson-Wikland
K
K
D000293:Adolescent; D000469:Alkaline Phosphatase / Q000097:blood; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006128:Growth / Q000187:drug effects; D006130:Growth Disorders / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013006:Growth Hormone / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000097:blood; D007335:Insulin-Like Growth Factor II / Q000097:blood; D008297:Male; D011347:Procollagen / Q000097:blood; D011627:Puberty
D011347:Procollagen; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013006:Growth Hormone; D000469:Alkaline Phosphatase